Publikationen 2022

Liebl M.C., Hofmann T.G. (2022) Regulating the p53 tumor suppressor network at PML biomolecular condensates, Cancers, 14, 4549

Solé-Boldo L., Raddatz G., Gutekunst J., Gilliam O., Bormann F., Liberio M.S., Hasche D., Antonopoulos W., Mallm J-P., Lonsdorf A.S., Rodríguez-Paredes M., Lyko F. (2022) Differentiation-related epigenomic changes define clinically disctinct keratinocyte cancer subclasses, Molecular Systems Biology, 18:e11073

Gómez-Marin E., Posavec-Marjanovic M., Zarzuela L., Basurto-Cayuela L., Guerreo-Martínez J.A., Arribas G., Yerbes R., Ceballos-Chávez M., Rodríguez-Paredes M., Tomé M., Durán R.V., Buschbeck M., Reyes J.C. (2022) The high mobility group protein HMG20A cooperates with the histone reader PHF14 to modulate TGFß and Hippo pathways, Nucleic Acids Research, 1-19, doi.org/10.1093/nar/gkac766

Beltzig L., Christmann C., Kaina B. (2022) Abrogation of cellular senescence induced by temozolomide in glioblastoma cels: search for senolytics, Cells, 11, 2588

Kaina B., Beltzig L., Strik H. (2022) Temozolomide - Just a radiosensitizer? Frontiers in Oncology, volume 12, article 912821. DOI: 10.3389/fonc.2022.912821

B. Vilar Juliana, Christmann M., Tomicic M.T. (2022) Alterations in molecular profiles affecting glioblastoma resistance to radiochemotherapy: Where does the good go? Cancers, 14, 2416

Beyer et al., (2022) Neuer Wirkstoff bekämpft effektiv Medikamenten-resistente Leukämiezellen, Cell Chemical Biology

Schneeweis C., Hassan Z., Ascherl K., Wirth M., Koutsouli S., Orben F., Krauß L., Schneider C., Öllinger R., Krämer O.H., Rad R., Reichert M., S. Robles M., Saur D., Schneider G. (2022) Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition, Cancer Commun. (Lond), 42(4), 360-364

Zeyen P., Zeyn Y., Herp D., Mahmoudi F., Z. Yesiloglu T., Erdmann F., Schmidt M., Robaa D., Romier C., Ridinger J., Herbst-Gervasoni C.J., W. Christianson D.W., Oehme I., Jung M., Krämer O.H., Sippl W. (2022) Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells, European Journal of Medicinal Chemistry, 234, 114272

Beltzig L., Schwarzenbach C., Leukel P., B.M. Frauenknecht K., Sommer C., Tancredi A., E.Hegi M., Christmann M., Kaina B. (2022) Senescence is the main trait induced by temozolomide in glioblastoma cells, Cancers, 14, 2233

Hanisch D., Krumm A., Diehl T., Stork C.M., Dejung M., Butter F., Kim E., Brenner W., Fritz G., Hofmann T.G., Roos W.P. (2022) Class I HDAC overexpression promotes temozolomide resistance in glioma cells by regulating RAD18 expression. Cell Death and Disease, 13:293

Traube F.R., Brás N.F., Roos W.P., Sommermann C.C., Diehl T., Mayer R.J., Ofial A.R., Müller M., Zipse H., Carell T. (2022) Epigenetic anti-cancer treatment with a stabilized carbocyclic decitabine analogue. Chemistry - A European Journal, e202200640

Petersen L., Stroh S., Schöttelndreier D., Grassl G.A., Rottner K., Brakebusch C., Fahrer J., Genth H. (2022) The essential role of Rac1 glucosylation in clostridioides difficile Toxin B-induced arrest of G1-S transition. Frontiers in Microbiology, Vol 13. Art. 846215

Doffo J., A. Bamopoulos S., Köse H., Orben F., Zang C., Pons M., T. den Dekker A., W.W. Brouwer R., Baluapuri A., Habringer S., Reichert M., Illendula A., Krämer O.H., Schick M., Wolf E., F.J. van Ijken W., Esposito I., Keller U., Schneider G., Wirth M. (2022) NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. PNAS, Vol. 119 No. 9 e2105691119

Krauß L., C.U. Bettina, Hastreiter S., Schneider C., Wenzel P., Hassan Z., Wirth M., Lankes K., Terrasi A., Klement C., M. Cernilogar F., Öllinger R., Krätzig N. de A., Engleitner T., Schmid R.M., Steiger K., Rad R., Krämer O.H., Reichert M., Schotta G., Saur D., Schneider G. (2022) HDAC2 facilitates pancreatic cancer metastasis. Cancer Research, 82:695-707

Lu L., Przybylla R., Shang Y., Dai M., Krohn M., Krämer O.H., Mullins C.S., Linnebacher M. (2022) Microsatellite status and IkBα expression levels predict sensitivity to pharmaceutical curcumin in colorectal cancer cells. Cancers, 14, 1032

Fauß J., Sprang B., Leukel P., Sommer C., Nikolova T., Ringel F., Kim E.L. (2022) ALDH1A3 segregated expression and nucleus-associated proteasomal degradation are common traits of glioblastoma stem cells. Biomedicines, 10, 7

Hill P., Zellmann F., Vukova T., Marini F., Kolmar S., Kaina B., Hofmann T.G., Nikolova T. (2022) Dose response to methylating agents in the γH2AX, SCE and colony formation assays: Effect of MGMT and MPG overexpression. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 876-877, 503462

Ibrahim H.S., Abdelsalam M., Zeyn Z., Zessin M., Mustafa Al-Hassan M., Fischer M.A., Zeyen P., Sun P., Bülbül E.F., Vecchio A., Erdmann F., Schmidt M., Robaa D., Barinka C., Romier C., Schutkowski M., Krämer O.H., Sippl W. (2022) Synthesis, molecular docking and biological characterization of pyrazine linked 2-aminobenzamides as new class I selective histone deacetylase (HDAC) inhibitors with anti-leukemic activity. International Journal of Molecular Sciences, 23, 269

Clemm von Hohenberg K., Müller S., Schleich S., Meister M., Bohlen J., Hofmann T.G., Teleman A.A. (2022) Cyclin B/CDK1 and Cyclin A/CDK2 phosphorylate DENR to promote mitotic protein translation and faithful cell division. Nature Communications, 13:668

Beyer M., Henninger S.J., Haehnel P.S., Mustafa Al-Hassan M., Gurdal E., Schubert B., Christmann C., Sellmer A., Mahboobi S., Drube S., Sippl W., Kindler T., Krämer O.H. (2022) Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells. Cell chemical Biology, 29, 1-14

Arnold C., Demuth P., Seiwert N., Wittmann S., Boengler K., Rasenberger B., Christmann C., Huber M., Brunner T., Linnebacher M., Fahrer J. (2022) The mitochondrial disruptor devimistat (CPI-613) synergizes with genotoxic anticancer drugs in colorectal cancer therapy in a bim-dependent manner. Molecular Cancer Therapeutics, 21:100-12